

IPOs

The following table includes the medical devices, biotechnology, pharmaceuticals, and healthcare IPO pricings, filings and withdrawals announced over the previous month.

Company Name	Last Financing Date	HQ Location	Description	Last Financing Size (Millions)	Lead Manager
Krystal Biotech (KRYA)	21-Aug-17	Pittsburgh, PA	Developer of gene therapy-based treatments for rare and orphan diseases.	35.00	Ladenburg Thalman & Co.

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Atelerix	1-Aug-17	Newcastle Upon Tyne, United Kingdom	Early Stage VC	Provider of a hydrogel encapsulation technology capable of preserving the viability and functionality of cells at hypothermic temperatures for cell storage and transport.	Undisclosed	Midven
BrightSpec	1-Aug-17	Charlottesville, VA	Early Stage VC	Provider of analytical chemistry solutions created for direct, non-destructive analysis of complex gas mixtures.	2.79	Undisclosed Investors
Day Zero Diagnostics	1-Aug-17	Allston, MA	Early Stage VC	Developer of a molecular diagnostic system combining whole genome sequencing and machine learning to speed the time to diagnose an infection and find its antibiotic resistance from days to hours.	1.00	Sands Capital Ventures
Homology Medicines	1-Aug-17	Bedford, MA	Early Stage VC	Developer of genetic medicines using proprietary gene editing and gene therapy technology designed to address rare diseases at the genetic level.	83.50	Deerfield Management, Fidelity Management and Research, Osage University Partners, Novartis, Rock Springs Capital, HBM Healthcare Investments, ARCH Venture Partners, Temasek Holdings, 5AM Ventures, Maverick Ventures, Vivo Capital, Vida Ventures, Alexandria Venture Investments

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Indalo Therapeutics	1-Aug-17	Saint Louis, MO	Early Stage VC	Operator of a biotechnology platform offering cutting-edge insight into the molecular drivers of aberrant scarring intended to develop novel treatments for fibrotic diseases.	8.99	BioGenerator, Missouri Technology, iSelect Fund, Orange Digital Ventures, Undisclosed Investors
JenaValve Technology	1-Aug-17	Munich, Germany	Later Stage VC	Manufacturer of second generation transcatheter aortic valve implantation systems for transapical and transfemoral implantation.	19.39	Undisclosed Investors
Milestone Pharmaceuticals	1-Aug-17	Saint-Laurent, Canada	Later Stage VC	Developer of a potent, self-delivered, and short-acting nasally-delivered calcium channel antagonist for the episodic treatment of paroxysmal supraventricular tachycardia, a cardiac arrhythmia.	55.00	Novo Holdings, Forbion Capital Partners, Tekla Capital Management, Domain Associates, Fonds de solidarité FTQ, BDC Capital, Pappas Capital, GO Capital
AgeX Therapeutics	2-Aug-17	Alameda, CA	Early Stage VC	Developer of pluripotent stem cell-derived brown adipocytes for the treatment of Type-2 diabetes, vascular progenitors to improve circulation to ischemic tissues in patients suffering from heart disease, and induced tissue regeneration designed to reprogram aged tissues in the body.	10.00	IBS Capital Kizoo Technology Capital, Jim Mellon

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Eloxx Pharmaceuticals	2-Aug-17	Rehovot, Israel	Later Stage VC	Developer of bio-pharmaceutical therapies designed to treat genetic diseases by restoring full-length functional proteins.	38.00	Pontifax Venture Capital, Life Sciences Partners & Phillip Forst, Catalyst CEL Fund, Quark Venture, GF Securities, Korea Investment Partners, DSC Investments, OPKO Health, Sevion Therapeutics
Immunocept	2-Aug-17	Denver, CO	Angel	Developer of a medical device to modulate the immune system's heightened call-to-action by removing inflammatory mediators through a controlled filtration process, enabling physicians to treat sepsis and other diseases of destructive inflammation.	0.53	Undisclosed Investors
Molecular Templates (MTEM)	2-Aug-17	Austin, TX	PIPE	Developer of a protein platform focused on the discovery and development of a new class of targeted biologic therapies based on engineered toxin bodies that possess unique mechanisms of action to address cancer and autoimmune diseases.	60.00	Longitude Capital, CAM Capital, BVF, Perceptive Advisors, Undisclosed Investors
TeleMD	2-Aug-17	Moscow, Russia	Early Stage VC	Developer of a clinical support system designed to diagnose and assess the risks of developing cancer on the analysis of medical images and other patient data.	0.18	Primer Capital
Causeway Therapeutics	3-Aug-17	Glasgow, United Kingdom	Seed Round	Provider of therapeutic services intended to offer treatment for tendon injury.	1.30	Mediqventures, Scottish Enterprise

Source: Pitchbook

Compiled by: Lea Keller and Morgan Reape

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Intarcia Therapeutics	3-Aug-17	Boston, MA	Later Stage VC	Developer of therapeutic products to enhance treatment outcomes by optimizing and improving the efficacy, continuous administration, and tolerability of drug therapies.	524.60	Kayon Partners and Baillie Gifford, Bill & Melinda Gates Foundation, SharesPost, Luxin Venture Capital, Fidelity Investments, RA Capital Management, Foresite Capital Management, The Pritzker Organization, The Baupost Group, Undisclosed Investors
Meissa Vaccines	3-Aug-17	South San Francisco, CA	Seed Round	Developer of vaccines created to prevent viral respiratory infections.	Undisclosed	FundRx
Micro C Imaging	3-Aug-17	Savannah, GA	Seed Round	Developer of a hand-held, wireless X-ray and digital imaging device that converts radiation to real-time static and dynamic fluoroscopic images, enabling surgeons, doctors, and healthcare providers to bring the X-ray source to the target to produce more resolute images.	0.80	Undisclosed Investors

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Auris Surgical Robotics	4-Aug-17	San Carlos, CA	Later Stage VC	Developer of surgical robotics and visualization technology for surgical applications that require very fine movements.	280.21	Coatue Management, Viking Global Investors, Section 32, Partner Fund Management, Mithril Capital Management, Lux Capital, Highland Capital, MedCap, Undisclosed Investors
Neovacs (ALNEV)	4-Aug-17	Paris, France	PIPE	Operator of a biotechnology company intended to develop therapeutic vaccines for the treatment of autoimmune and inflammatory diseases using its proprietary Kinoid technology.	15.95	Undisclosed Investors
Resonant Therapeutics	4-Aug-17	Santa Barbara, CA	Early Stage VC	Developer of therapeutics, including novel targets and anti-tumor antibodies with high affinity and unprecedented speed, designed to treat cancer.	1.39	Mercury Fund, Undisclosed Investors
Sonacare Medical	4-Aug-17	Charlotte, NC	PE Growth/Expansion	Provider of ultrasound technologies for treating prostate diseases.	3.00	Decathlon Capital Partners
Stealth Therapeutics	4-Aug-17	Madison, WI	Later Stage VC	Developer of micro-invasive intravenous port products.	0.14	Undisclosed Investors
Vanc Pharmaceuticals (VANC)	4-Aug-17	Richmond, Canada	PIPE	Manufacturer and distributor of generic and over-the-counter pharmaceuticals.	0.16	Undisclosed Investors
AltMed	7-Aug-17	Sarasota, FL	Angel	Developer of cannabis-based therapies.	10.50	Undisclosed Investors
Clinical Trial Center	7-Aug-17	Rome, Italy	PE Growth/Expansion	Provider of clinical research and trial training services in the study of new drugs and devices.	Undisclosed	Principia SGR

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Karius	7-Aug-17	Menlo Park, CA	Early Stage VC	Developer of a molecular biology and data analysis tool that harnesses next-generation sequencing to diagnose and treat infectious diseases by detecting fragments of cell-free DNA from bacteria, viruses, fungi, and protozoa that may be circulating in a patient's bloodstream.	50.00	Data Collective and Lightspeed Venture Partners, Tencent, Khosla Ventures, Innovation Endeavors, Spectrum 28
V ClinBio	7-Aug-17	Newark, NJ	Angel	Provider of medical research services intended to develop drug products for the treatment of immune and other related diseases.	3.90	Undisclosed Investors
Fyodor Biotechnologies	8-Aug-17	Baltimore, MD	Accelerator/ Incubator	Developer of a non-invasive technology designed to diagnose malaria with urine.	0.15	500 Startups
Go Therapeutics	8-Aug-17	Cambridge, MA	Corporate	Provider of a scientific platform for modified T-cell-based therapies and antibody-drug conjugates that make antibodies to hybrid antigens combining a tumor's up-regulated protein express with that of a protein's aberrant glycosylation pattern, enabling patients to receive treatment for cancer without destroying any healthy tissue.	5.00	Undisclosed Investors
Just Biotherapeutics	8-Aug-17	Seattle, WA	Early Stage VC	Designer of a set of dynamic research and development tools for molecular design, process and product design, and manufacturing plant design for antibody and recombinant protein bio-therapeutics.	59.00	Temasek, Hangzhou Economic and Technological Development Area, Lilly Asia Ventures, ARCH Venture Partners, Taikang, Bank of China, Bank of Hangzhou

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Evofem	9-Aug-17	San Diego, CA	Later Stage VC	Developer of a proprietary vaginal gel for women's evolving sexual and reproductive health needs, including contraception and the prevention of STIs.	7.50	Undisclosed Investors
Koye	9-Aug-17	Mumbai, India	Later Stage VC	Provider of specialty care drugs for inflammatory conditions.	Undisclosed	InnoVen Capital
Molecular Assemblies	9-Aug-17	San Diego, CA	Seed Round	Developer of deoxyribonucleic acid synthesis technology.	4.54	Agilent Technologies, Cavendish Impact Capital Fund, Eleven Two Capital, Data Collective, Keshif Ventures, Genomics Investment Syndicate, Newport Holdings, Alexandria Venture Investments, Undisclosed Investors
Roivant Sciences	9-Aug-17	New York, NY	PE Growth/Expansion	Operator of a bio-pharmaceutical company designed to reduce the time and cost of the drug development process.	1100.00	Softbank Group, Dexcel Pharma
Zimmer BioTech	9-Aug-17	Neu-Ulm, Germany	Seed Round	Developer of drug research and development services intended to be used in the treatment of actinic keratoses in combination with photodynamic therapy.	8.06	High-Tech Gründerfonds, Zimmer MedizinSysteme

Source: Pitchbook

Compiled by: Lea Keller and Morgan Reape

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Amyris (AMRS)	10-Aug-17	Emeryville, CA	PIPE	Provider of technology that supports disruptive product development and rapid time to market in nutraceuticals, drug discovery, and manufacturing.	50.00	Koninklijke DSM, Vivo Capital
Apellis	10-Aug-17	Crestwood, KY	Later Stage VC	Developer of a bio-pharmaceutical platform to treat paroxysmal nocturnal hemoglobinuria, geographic atrophy, intermediate age-related macular degeneration, and chronic obstructive pulmonary disease.	60.00	Sectoral Asset Management, Sofinnova, Vivo Capital, F-Prime Capital Partners, venBio, Morningside Group, Cormorant Asset Management, Epidarex Capital, Undisclosed Investors
Arch BioPartners (ARCH)	10-Aug-17	Toronto, Canada	PIPE	Developer of diagnosis and treatment methods for acute and chronic diseases.	0.16	Undisclosed Investors
Centrose	10-Aug-17	Madison, WI	Later Stage VC	Developer of targeted medicines designed to eliminate side effects and increase drug potency to treat advanced forms of cancer and other difficult to treat diseases.	0.20	Undisclosed Investors
IsoPlexis	10-Aug-17	Branford, CT	Early Stage VC	Developer of multiplexed single-cell analysis tools that provide in-depth biological characterization of immune and cancer cell subsets among heterogeneous populations, enabling researchers and clinicians to generate clear solutions to complex patient response.	11.15	Connecticut Innovations, Undisclosed Investors
Kurin	10-Aug-17	San Diego, CA	Angel	Provider of a software platform that offers healthcare service providers guidelines to manage wastage and risk associated with hospitality procedures.	2.39	Undisclosed Investors
Signature Orthodontics	10-Aug-17	Boston, MA	Angel	Developer of a next-generation manufacturing technology adapted for use in orthodontic treatment.	1.30	Undisclosed Investors

Source: Pitchbook

Compiled by: Lea Keller and Morgan Reape

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Greffex	11-Aug-17	Aurora, CO	Angel	Developer of a universal platform for the development and production of vaccines against a wide variety of infectious diseases.	0.16	Undisclosed Investors
Levo Therapeutics	11-Aug-17	Glenview, IL	Early Stage VC	Provider of biomedical research and development services intended to treat multisystem neurodevelopmental disorders.	46.92	Samsara BioCapital, Undisclosed Investors
Cardiac Insight	14-Aug-17	Kirkland, WA	Later Stage VC	Developer of CardeaScreen, a body-worn sensing and computing monitor for applications in cardiology, respiratory assessments, and other complex disease states.	3.83	Undisclosed Investors
Eyenovia	14-Aug-17	New York, NY	Early Stage VC	Provider of an ophthalmic microdrops technology for glaucoma, allergic eye disease, dry eye, and other eye diseases.	10.04	Undisclosed Investors
Freenome	14-Aug-17	San Francisco, CA	Early Stage VC	Developer of a biotechnology created to bring accurate, accessible, and non-invasive disease screening for the treatment of cancer and other diseases.	72.00	Andreessen Horowitz, Data Collective, Founders Fund, GV, Polaris Partners, Innovation Endeavors, Asset Management Ventures, Charles River Ventures, Spectrum 28, Anne Wojcicki, Verily Life Sciences, Undisclosed Investors
Modulated Imaging	14-Aug-17	Irvine, CA	Later Stage VC	Developer of light-based methods for medical diagnostics.	2.00	Undisclosed Investors

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
BioQ Pharma	15-Aug-17	San Francisco, CA	PE Growth/Expansion	Developer and supplier of infusible pharmaceuticals, including pre-filled and unit-dose drug-infusion pharmaceuticals.	73.30	Visionary Private Equity Group, Madryn Asset Management, Undisclosed Investors
Carevive Systems	15-Aug-17	Philadelphia, PA	Early Stage VC	Developer of a clinical practice and patient engagement software designed to improve outcomes with comprehensive patient care plans.	7.25	HLM Venture Partners, Long River Ventures, Undisclosed Investors
Curasight	15-Aug-17	Copenhagen, Denmark	Secondary Transaction - Private	Provider of PET imaging ligands for the treatment of prostate cancer.	Undisclosed	Undisclosed Investors
Microbiome Insights	15-Aug-17	Vancouver, Canada	Early Stage VC	Provider of a microbiome bioinformatics platform designed to offer microbiome sample testing and analysis services.	0.17	Undisclosed Investors
NGX Bio	15-Aug-17	San Francisco, CA	Seed Round	Provider of an online marketplace designed for DNA sequencing services.	1.50	180 Degree Capital, Third Kind Venture Capital, Lateral Capital, Band of Angels, Berkeley Angel Network, Undisclosed Investors

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Neuros Medical	15-Aug-17	Willoughby Hills, OH	Later Stage VC	Operator of a medical device company developing neurostimulation technology for the treatment of chronic pain.	22.63	U.S. Venture Partners, Boston Scientific, Aperture Venture Partners, Osage University Partners, iSelect Fund, JumpStart, Undisclosed Investors
Orbus Therapeutics	15-Aug-17	Palo Alto, CA	Early Stage VC	Developer of Eflornithine, an irreversible inhibitor of ornithine decarboxylase that delays or freezes tumor growth by inhibiting production of the enzyme that can cause tumor growth in certain types of cancer.	12.50	Undisclosed Investors
Synreca Pharmaceuticals	15-Aug-17	Oklahoma City, OK	Later Stage VC	Developer of orally active drugs designed to address the growing problem of bacterial resistance to current antibiotics.	0.60	Undisclosed Investors
Axol Biosciences	16-Aug-17	Cambridgeshire, United Kingdom	PE Growth/Expansion	Developer of iPSC-derived cells that are reprogrammed using stem cell technology to produce human cells for biomedical research.	3.25	Calculus Capital
Color Genomics	16-Aug-17	Burlingame, CA	Later Stage VC	Provider of an online healthcare kit that provides individuals with testing services from certified medical professionals for early detection of various forms of cancer.	80.00	General Catalyst Partners, Emerson Collective, CRV, Undisclosed Investors
Alzeca Biosciences	17-Aug-17	Houston, TX	PE Growth/Expansion	Developer of advanced novel, targeted magnetic resonance imaging agents for the early detection and diagnosis of Alzheimer's disease and other neurodegenerative diseases.	11.00	Undisclosed Investors
Atreca	17-Aug-17	Redwood City, CA	Early Stage VC	Developer of novel therapeutics designed to engage the human immune response in oncology and other indications.	35.00	Wellington Management, Cormorant Asset Management, Undisclosed Investors

Source: Pitchbook

Compiled by: Lea Keller and Morgan Reape

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Mapi Pharma	17-Aug-17	Ness Ziona, Israel	Later Stage VC	Developer of a once monthly injection for the treatment of multiple sclerosis.	10.00	aMoon Fund
Pinteon Therapeutics	17-Aug-17	Concord, MA	Early Stage VC	Developer of cancer therapeutics targeting a cis-trans isomerase.	10.01	Morningside Technology Ventures, Undisclosed Investors
Biofortuna	18-Aug-17	Wirral, United Kingdom	Later Stage VC	Developer of molecular diagnostic and freeze dried technology designed to offer both custom manufacturing services and molecular diagnostic products.	2.08	Foresight Group, Undisclosed Investors
Fog Pharmaceuticals	18-Aug-17	Boston, MA	Early Stage VC	Developer of transformative medicine that uses cell-penetrating miniproteins to access validated intracellular disease drivers and for honing of therapeutically beneficial tissues.	11.00	Deerfield Management, Undisclosed Investors
Perlara	18-Aug-17	San Francisco, CA	Early Stage VC	Provider of a platform engaged in the discovery of personalized treatments for rare genetic diseases.	4.14	Undisclosed Investors
Celularity	21-Aug-17	Warren, NJ	Early Stage VC	Provider of bio-technical research and development services intended to harness the power of placenta-derived cells and tissues to amplify the body's ability to fight disease and regenerate itself.	185.00	Sorrento Therapeutics, United Therapeutics Corporation, Human Longevity, Undisclosed Investors
GNS Healthcare	21-Aug-17	Cambridge, MA	Later Stage VC	Provider of a big data analytics platform for precision medicine and population health.	6.00	Amgen Ventures, Alexandria Real Estate Equities
MindImmune Therapeutics	21-Aug-17	RI	Seed Round	Developer of drugs to treat diseases of the central nervous system, including Huntington disease, Alzheimer's, pain, and psychiatric disorders.	0.50	Slater Technology Fund, Undisclosed Investors

Source: Pitchbook

Compiled by: Lea Keller and Morgan Reape

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Morphogenesis	21-Aug-17	Tampa, FL	Angel	Developer of a multi-indication therapeutic cancer vaccine that directs the patient's own immune system to attack tumor cells throughout the body without damaging normal cells or tissues.	1.75	Undisclosed Investors
OncoBox	21-Aug-17	Walnut, CA	Accelerator/ Incubator	Provider of personalized genetic profiling intended to find the right cancer drug for each patient.	0.12	Y Combinator
Oxford Genetics	21-Aug-17	Oxford, United Kingdom	Later Stage VC	Developer of innovative synthetic biology-based technologies designed to create transformative systems and services to aid in the discovery and development of biologics, cell, and gene therapies.	9.75	Mercia Technologies, Invesco Perpetual
Unity Biotechnology	21-Aug-17	Brisbane, CA	Early Stage VC	Provider of therapeutics designed to prevent, halt or reverse diseases associated with aging, including osteoarthritis, glaucoma, heart disease and kidney failure.	151.23	ARCH Venture Partners, Invus Group and Mayo Clinic Ventures, Venrock, Three Lakes Partners, Cycad Group, COM Investments, Pivotal Alpha, Partner Fund Management, Baillie Gifford, Bezos Expeditions, Fidelity Management & Research, Vulcan Capital, The longevity fund, Founders fund, WuXi Healthcare Ventures, Undisclosed Investors

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Bone Biologics (BBLG)	22-Aug-17	Boston, MA	PIPE	Operator of a biotechnology company focused on developing bone graft substitute for spine fusion.	1.40	Musculoskeletal Transplant Foundation, Hankey Capital
Elucida Oncology	22-Aug-17	New York, NY	Early Stage VC	Developer of an ultra-small nano particle delivery platform centered around the detection and treatment of primary solid tumor and metastatic cancers.	10.86	Undisclosed Investors
Helix Nanotechnologies	22-Aug-17	Beerse, Belgium	Accelerator/ Incubator	Provider of software focused on DNA nanotechnology that helps in creation of drugs required for the treatment of patients' muscles via synthetic biology.	0.12	Y Combinator
Apic Bio	23-Aug-17	Winchester, MA	Seed Round	Developer of a gene therapy platform to treat rare diseases with complex mechanisms.	1.00	Alpha 1 Foundation, Ed Krapels
Hercules (Pharmaceuticals)	23-Aug-17	Leiden, Netherlands	Angel	Developer of drugs for the treatment of cancer vulnerabilities that help in enhancing the immune system, reducing metastatic behavior and aggression of existing cancer, making cancer cells sensitive, and eliminating the chance of future relapses.	0.35	uniiq
ImmunoPrecise Antibodies (IPA)	23-Aug-17	Victoria, Canada	PIPE	Supplier of custom monoclonal and polyclonal antibodies capable of binding to specific target molecules, or antigens, used widely in research assays, diagnostics, purification, and therapeutics.	5.25	Undisclosed Investors
Macrophage Pharma	23-Aug-17	Berkhamsted, United Kingdom	Early Stage VC	Developer of novel therapies to enhance anti-tumour immune responses to boost up the body's natural immune system to fight cancer.	Undisclosed	Cancer Research Technology, Sixth Element Capital, Aglaia Biomedical Ventures, Merck Ventures, Novo
SynAgile	24-Aug-17	Wilson, WY	Later Stage VC	Developer of an infusion therapy designed to enable patients to achieve stable plasma L-DOPA concentrations and to provide convenient, noninvasive, continuous dopaminergic stimulation.	10.40	Affiliates of TAMCAP
eXIthera Pharmaceuticals	24-Aug-17	Westborough, MA	Later Stage VC	Developer of an early stage biotechnology platform focused on developing drugs based on Factor XI.	3.00	Undisclosed Investors

Source: Pitchbook

Compiled by: Lea Keller and Morgan Reape

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Biocare Medical (IHC instrumentation)	25-Aug-17	Pacheco, CA	PE Growth/Expansion	Developer of a portfolio of integrated tissue diagnostic products for cancer, infectious diseases, and immunohistochemistry, and molecular pathology products.	Undisclosed	Excellere Partners
Carmot Therapeutics	25-Aug-17	San Francisco, CA	Later Stage VC	Developer of drugs made with proprietary Chemotype Evolution technology that help in the rapid identification of novel drugs through an evolutionary lead-identification paradigm for the treatment of metabolic diseases, cancer, and inflammation.	10.79	Undisclosed Investors
CF PharmTech	28-Aug-17	Suzhou, China	Later Stage VC	Developer and manufacturer of a metered dose inhaler, inhalation powder, nasal spray, and blow-fill-seal products for the treatment of asthma, COPD, and allergic rhinitis.	65.00	SDIC Innovation Investment Management, 1314fund, IRSE Capital, Le Jin Capital, CCB International Asset Management, Longpan Capital, Wim Asset management, Xin Ding Zi Ben, YuanMing Capital, Undisclosed Investors
J3 Bioscience	28-Aug-17	Salt Lake City, UT	Angel	Developer of biomedical devices that help females improve their reproduction health.	0.94	Undisclosed Investors

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Medgenome	28-Aug-17	Foster City, CA	Later Stage VC	Provider of a genomics-based diagnostics and research platform that applies genomics technologies, bioinformatics, computing, and big data analytics to the genetically diverse and large population to understand the genetic basis of cancer, metabolic disorders, eye disorders, and other rare diseases.	30.00	Sofina and Sequoia Capital India, Zodius Capital, Kris Gopalakrishnan, Lakshmi Narayanan
OrthAlign	28-Aug-17	Aliso Viejo, CA	Later Stage VC	Developer of computer assisted surgical navigation systems designed for both total knee and total hip arthroplasty surgeries.	7.60	Undisclosed Investors
SetPoint Medical	28-Aug-17	Santa Clarita, CA	Later Stage VC	Developer of implantable neuromodulation devices designed to offer treatment of chronic inflammatory diseases.	30.00	New Enterprise Associates, Morgenthaler Ventures and Medtronic Ventures, Boston Scientific, Topspin, Action Potential Venture Capital, Undisclosed Investors
SymbioCellTech	28-Aug-17	Salt Lake City, UT	Later Stage VC	Developer of cell-based therapies, including an adult stem cell-based therapy for the cure of insulin-dependent Type-1 diabetes.	1.91	Undisclosed Investors

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
ARMO BioSciences	29-Aug-17	Redwood City, CA	Later Stage VC	Developer of immunotherapeutics designed to activate the immune system of cancer patients to recognize and eradicate tumors.	67.00	Qiming Venture Partners, Decheng Capital, Sequoia Capital, Quan Funds, RTW Investments, Kleiner Perkins Caufield & Byers, OrbiMed, DAG Ventures, NanoDimension, HBM Healthcare Investments, GV, Celgene, Clough Capital Partners
Akeso Biopharma	29-Aug-17	Zhongshan, China	Early Stage VC	Developer of antibody drugs to treat oncology, inflammation, autoimmune, and cardiovascular diseases.	44.29	Shenzhen GTJA Investment Group, Shenzhen Capital Group, Qianhai Fund of Funds, Triwise Capital
IRX Therapeutics	29-Aug-17	New York, NY	Early Stage VC	Developer of therapies designed to activate a patient's immune system to defeat cancer and related diseases.	33.23	Disruptive Capital Finance, Undisclosed Investors

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
RareCyte	29-Aug-17	Seattle, WA	PE Growth/Expansion	Provider of a life science research and diagnostic development platform intended for characterizing and isolating rare cells in the blood.	30.00	5AM Ventures, Telegraph Hill Partners, Ronald Seubert, Undisclosed Investors
Torque Therapeutics	29-Aug-17	Cambridge, MA	Early Stage VC	Developer of an online platform for providing immunotherapy services.	21.00	Flagship Ventures, Undisclosed Investors
Motif Bio (MTFB)	30-Aug-17	New York, NY	Secondary Transaction - Private	Developer of novel antibiotics designed to treat serious and life-threatening infections caused by multi-drug resistant bacteria.	Undisclosed	Undisclosed Investors
Notable Labs	30-Aug-17	San Francisco, CA	Early Stage VC	Provider of a platform that enables doctors to seek and evaluate combinations of FDA-approved treatments for patients with brain cancer.	22.04	Great Oaks Venture Capital, Undisclosed Investors
Peptilogics	30-Aug-17	Pittsburgh, PA	Early Stage VC	Developer of a technology platform for designing novel peptide antibiotics that inactivate drug-resistant bacteria for rapid selection.	4.75	Undisclosed Investors
Akadeum Life Sciences	31-Aug-17	Ann Arbor, MI	Early Stage VC	Developer of a two-parameter separation technology designed to improve cell isolation from complex samples.	1.48	Undisclosed Investors
DiscGenics	31-Aug-17	Salt Lake City, UT	Early Stage VC	Operator of a biotechnology company developing and commercializing advanced spinal therapeutics intended to treat patients with diseases of the intervertebral disc.	14.00	Undisclosed Investors
Gemofarm	31-Aug-17	Moscow, Russia	Early Stage VC	Developer of a drug for patients with multiple myeloma.	Undisclosed	Primer Capital

Mergers and Acquisitions

The following table includes mergers and acquisitions for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.					
Acquirer	Target	HQ Location	Date	Description	Transaction Value (Millions)
NantCell	Altor BioScience	Miramar, FL	1-Aug-17	Developer of immunotherapies on engineered cytokine technology platforms designed to treat cancer and viral infections.	1080.00
Fagron	Kemig	Donja Zelina, Croatia	1-Aug-17	Supplier of pharmaceutical raw materials and packaging materials.	Undisclosed
Achieve Life Sciences	OncoGenex Pharmaceuticals	Bothell, WA	1-Aug-17	Developer of novel therapeutics designed to target key mechanisms of treatment resistance in cancer.	Undisclosed
Collidion	Plex Pharmaceuticals	San Diego, CA	2-Aug-17	Provider of a drug discovery platform combining functional fragment screening with X-ray crystallography co-crystallization created to focus on diseases caused by protein misfolding.	Undisclosed
Genesis Biotechnology Group	4path	Burr Ridge, IL	3-Aug-17	Provider of anatomic pathology services, including diagnostic and laboratory test facilities with expertise in podiatry, gastroenterology, urology, dermatology, breast, gynecology, orthopedics, and other specialties.	Undisclosed
Anything Technologies Media	Shield Global	Jupiter, FL	3-Aug-17	Developer of organic antimicrobial products and solutions.	Undisclosed
CSL	Wuhan Zhong Yuan Rui De Biological Products	Wuhan, China	3-Aug-17	Manufacturer and developer of plasma derived products.	352.00
Charles River	Brains On-Line	South San Francisco, CA	7-Aug-17	Researcher and developer of drugs offering sophisticated in vivo efficacy and pharmacokinetics testing to provide critical data required to advance potential CNS therapies through the development process.	28.44
Shenzhen Eternal Asia Medical Supply Chain Management	Yunnan Tengrui Pharmaceutical	China	7-Aug-17	Supplier of Chinese medicine and pharmaceutical products.	3.19
Aclaris Therapeutics	Confluence Life Sciences	Saint Louis, MO	8-Aug-17	Developer of kinase inhibitors that target key enzymes involved in the regulation of cancer growth, survival, and metastasis, or in reduction of chronic inflammation, to treat cancer and inflammatory disease.	100.00
Sopharma	Medica	Sofia, Bulgaria	9-Aug-17	Manufacturer of medical devices and generic pharmaceutical products.	Undisclosed
Evotec	Aptuit	Greenwich, CT	11-Aug-17	Provider of drug development services offering highly synergistic scientific expertise across drug discovery, pre-clinical testing, and both drug substance and drug product manufacturing.	300.00

Source: Pitchbook

Compiled by: Lea Keller and Morgan Reape

Mergers and Acquisitions

The following table includes mergers and acquisitions for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Acquirer	Target	HQ Location	Date	Description	Transaction Value (Millions)
Aurora Optoelectronics	Southwest Pharmaceutical (acquired in 2014)	Chongqing, China	11-Aug-17	Manufacturer and distributor of pharmaceutical products, including vitamin K, phenylethylbarbituric acid, vitamin D, and other related medicines.	608.22
Jiangxi Boya Bio-pharmaceutical Company	Hainan Tianhuang Pharmaceutical	Haikou, China	14-Aug-17	Manufacturer and distributor of pharmaceutical products, including cefoxitin sodium for injection, nourishing solid capsules, and other related medicines.	Undisclosed
Cancer Genetics	vivoPharm	Bundoora, Australia	14-Aug-17	Provider of a pre-clinical testing platform intended to offer pharmacology, toxicology, and bioanalytical research services to guide drug development.	12.00
Decision Resources Group	Context Matters	New York, NY	16-Aug-17	Developer of an online health economics data platform designed to modernize and improve the process of valuing drug therapies.	Undisclosed
Indoor Harvest	Alamo CBD	TX	23-Aug-17	Producer of medical grade cannabidiol oil.	0.01
ImmunoPrecise Antibodies	U-Protein Express	Utrecht, Netherlands	23-Aug-17	Operator of a contract research platform offering fast and large-scale production of recombinant proteins and antibodies for research and pre-clinical applications.	7.86
Synlogic	Mirna Therapeutics	Austin, TX	28-Aug-17	Developer of micro ribonucleic acid-based oncology therapeutics that kills cancer cells by regaining control over multiple oncogenic pathways.	Undisclosed
Sanofi	Protein Sciences	Meriden, CT	28-Aug-17	Developer and producer of vaccines and proteins for influenza, SARS, and other diseases.	750.00
Canopy Growth	Spot Therapeutics	Fredericton, Canada	28-Aug-17	Provider of cannabis-based products.	1.77
Thermo Fisher Scientific	Patheon	Durham, NC	29-Aug-17	Provider of pharmaceutical development and manufacturing services.	5200.00
Arrow Pharmaceuticals	Amneal Pharma Australia	South Yarra, Australia	31-Aug-17	Retailer and distributor of generic medicines and branded over-the-counter products.	13.24
Horizon Discovery	GE Healthcare Dharmacon	Lafayette, CO	31-Aug-17	Provider of research tools for gene knockdown, microRNA, RNAi screening, gene expression, and genome editing.	85.00